tbuckley/cabot-search huggingface dataset:
Dual role of<i>Helicobacter</i>and<i>Campylobacter</i>species in IBD: a systematic review and meta-analysis
Authors: Natalia Castaño-Rodríguez, Nadeem O Kaakoush, Way Seah Lee, Hazel M Mitchell
Journal: Gut (2015)

<h3>Objective</h3> To conduct a comprehensive global systematic review and meta-analysis on the association between <i>Helicobacter pylori</i> infection and IBD. As bacterial antigen cross-reactivity has been postulated to be involved in this association, published data on enterohepatic <i>Helicobacter</i> spp (EHS) and <i>Campylobacter</i> spp and IBD was also analysed. <h3>Design</h3> Electronic databases were searched up to July 2015 for all case-control studies on <i>H. pylori</i> infection/EHS/<i>Campylobacter</i> spp and IBD. Pooled ORs (P-OR) and 95% CIs were obtained using the random effects model. Heterogeneity, sensitivity and stratified analyses were performed. <h3>Results</h3> Analyses comprising patients with Crohn9s disease (CD), UC and IBD unclassified (IBDU), showed a consistent negative association between gastric <i>H. pylori</i> infection and IBD (P-OR: 0.43, p value &lt;1e-10). This association appears to be stronger in patients with CD (P-OR: 0.38, p value &lt;1e-10) and IBDU (P-OR: 0.43, p value=0.008) than UC (P-OR: 0.53, p value &lt;1e-10). Stratification by age, ethnicity and medications showed significant results. In contrast to gastric <i>H. pylori</i>, non <i>H. pylori</i>-EHS (P-OR: 2.62, p value=0.001) and <i>Campylobacter</i> spp, in particular <i>C. concisus</i> (P-OR: 3.76, p value=0.006) and <i>C. showae</i> (P-OR: 2.39, p value=0.027), increase IBD risk. <h3>Conclusions</h3> <i>H. pylori</i> infection is negatively associated with IBD regardless of ethnicity, age, <i>H. pylori</i> detection methods and previous use of aminosalicylates and corticosteroids. Antibiotics influenced the magnitude of this association. Closely related bacteria including EHS and <i>Campylobacter</i> spp increase the risk of IBD. These results infer that <i>H. pylori</i> might exert an immunomodulatory effect in IBD.
Abstract 12161: Dipeptidyl Peptidase IV Inhibitor Therapy Modifies Systolic Blood Pressure in High Blood Pressure Diabetic Patients: Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) 2 Trial
Authors: Hirofumi Soejima, Takeshi Morimoto, Sadanori Okada, Mio Sakuma, Masafumi Nakayama, Shiro Uemura, Masao Kanauchi, Naofumi Doi, Hideaki Jinnouchi, Seigo Sugiyama, Masako Waki, Yoshihiko Saito, Hisao Ogawa
Journal: Circulation (2014)

Introduction: It has been reported that dipeptidyl peptidase (DPP) IV inhibitor treatment increased glucagon like peptide (GLP)-1 and GLP-1 receptor expression levels, and subsequently endothelial nitric oxide synthase levels in experimental studies. It is possible that DPP IV inhibitors modify blood pressure (BP) through the improvement of endothelial function. Hypothesis: The aim of this study was to investigate whether DPP IV inhibitors ameliorated BP in diabetic patients. Methods: The JPAD trial, 2002 to 2008, a multicenter, prospective, randomized, open label, blinded, end-point study, was undertaken to examine the efficacy of aspirin therapy. After completion of the trial in 2008, we followed the same subjects until 2013 as JPAD2 trial cohort. BP was measured in 1244 patients in both 2009 and 2013. Among the 1244 patients, 4 patients received DPPIV inhibitors in 2009, 280 patients in 2011, 573 patients in 2013. We examined the change of BP in the 573 patients. Among them, 344 patients had systolic BP≥140 mmHg or diastolic BP≥90 mmHg or both (high BP group). Results: The systolic BP from 2009 to 2013 did not significantly change in the 1244 patients (Figure). The diastolic BP significantly decreased in the 1244 patients (Figure). The systolic BP from 2009 to 2013 did not significantly change in the 573 patients receiving DPPIV inhibitors (Figure). The diastolic BP significantly decreased in the 573 patients receiving DPPIV inhibitors (Figure). In the high BP group, the systolic BP from 2009 to 2013 significantly decreased in the 148 patients receiving DPPIV inhibitors (Figure). In the high BP group, the diastolic BP significantly decreased in the 148 patients receiving DPPIV inhibitors (Figure). Conclusions: In 4 year-observation of the JPAD2 trial cohort, diastolic BP decreased and systolic BP did not change in diabetic patients. User of DPPIV inhibitors has been dramatically increased, and it significantly modifies systolic BP in high BP diabetic patients.
Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome.
Authors: L Brugieres, O Hartmann, J P Travagli, E Benhamou, J L Pico, D Valteau, C Kalifa, C Patte, F Flamant, J Lemerle
Journal: Journal of Clinical Oncology (1989)

Two hundred ninety-one courses of high-dose chemotherapy (HDC) with bone marrow transplantation (BMT) in children with malignancies were reviewed in order to assess the incidence, clinical course, outcome, and predisposing factors of hemorrhagic cystitis. Hemorrhagic cystitis occurred in 19 HDC courses (6.5%). Three patients had grade I hematuria linked to thrombopenia, nine had grade II hematuria despite platelet levels greater than 50 x 10(9)/L, and seven had grade III hematuria with clots and bladder obstruction. Severe complications occurred in grade III patients, but no deaths were directly linked to the cystitis. Fourteen patients recovered within two to 120 days of onset. The other patients died before the cystitis resolved, either of a relapse of the malignancy or of infection. Predisposing factors were age (increased incidence in older children), conditioning regimen containing cyclophosphamide, previous vesical irradiation, association with prolonged aplasia, and hepatic complications. The role of busulfan was also probable. No viral agent was found.
VOLUNTARY MALE STERILIZATION
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Competition and Biosimilar Products—Reply
Authors: Amitabh Chandra, Jacqueline Vanderpuye-Orgle
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions
Authors: Matthieu Picard, Leyla Pur, Joana Caiado, Pedro Giavina-Bianchi, Violeta Regnier Galvão, Suzanne T. Berlin, Susana M. Campos, Ursula A. Matulonis, Mariana C. Castells
Journal: Journal of Allergy and Clinical Immunology (2015)
Make a ‘Pact’ with good health, you cannot afford not to!
Authors: Steffan Griffin
Journal: British Journal of Sports Medicine (2015)

Health and Fitness.

Requires iOS 6.0 or more recent on Apple products. Requires Android 2.3 (‘Gingerbread’) or more recent on other products.

Free for the app. Variable financial incentives for fulfilling individual pacts while financial penalty (user determinable) applies for not completing pacts.

Tools that demonstrate the amount of steps taken,1 distance covered and even caloric expenditure are now ubiquitous, but can apps promote positive health behaviours? Or is it too easy to ignore the figures and find an excuse?2

‘Pact’ is an app that does exactly what it says on the tin—it lets you make a pact with yourself to exercise or diet, and then rewards you financially for fulfilling …
Abstract 12309: Relationship Between Pressure and Flow Waveforms in Cerebral Arteries of 1020 Subjects: Establishing Normal Values
Authors: MiOk Kim, Yan Li, Fangfei Wei, Jiguang Wang, Michael F O’Rourke, Alberto Avolio
Journal: Circulation (2014)

In order to obtain new information on diagnosis and monitoring of cerebrovascular disease, it is desirable to know normal values and change with age of cerebral artery pressure and flow waves. Such information does not presently exist.

Flow waveforms (transcranial Doppler) were measured in 1020 normal subjects undergoing 24-hour BP monitoring to exclude diagnosis of hypertension at Ruijin Hospital, Shanghai. Central aortic pressure wave was generated using validated SphygmoCor generalized transfer function (K002742) from the radial artery wave measured at the wrist by applanation tonometry, and taken as a surrogate of pressure at entry into the carotid canal. Relationship were described in the time domain as Flow Augmentation Index (FAIx) vs Pressure AIx (PAIx). Relationship in the frequency domain was described as impedance. FAIx was flow augmentation ÷ flow wave amplitude and PAIx was pressure augmentation ÷ pressure wave amplitude.

Flow waves were similar in cerebral arteries, with flow velocity positive throughout diastole in all subjects and with no backflow. Peak flow velocity (45-85 cm/s) was similar to that in the carotid and other systemic arteries. Amplitude of pressure waves and PAIx increased with age. Amplitude of flow waves did not increase with age, but FAIx did, with linear relationship to PAIx. Cerebral vascular impedance was low and phase difference small, with fluctuations indicative of Wave Reflection, but with reflection magnitude <40%, and less than other vascular beds excepting the kidney and lungs. As with AIx relationship in the time domain, there was little or no change in impedance with age, and little or no gender difference.

Findings provide normal values against which measurements in disease states can be compared. Findings are consistent with those in vascular beds in lungs and kidney, but do not show aging changes as described in the ascending aorta for the whole systemic circulation.
Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients
Authors: Eileen M Boyle, Brian A Walker, Christopher P Wardell, Alexander Murison, Lorenzo Melchor, Martin F Kaiser, Dil Begum, Paula Proszek, Nasrin Dahir, David C Johnson, Charlotte Pawlyn, John Jones, Fabio Mirabella, Annamaria Brioli, Aneta Mikulasova, David A Cairns, Walter Gregory, Ana Quartilho, Mark T Drayson, Nigel Russell, Gordon Cook, Graham H Jackson, Faith E Davies, Gareth J. Morgan
Journal: Blood (2014)
Phase II studies of BEZ235 in patients with advanced pancreatic neuroendocrine tumors (pNET).
Authors: Ramon Salazar, Chris Verslype, Eric Baudin, Steven K. Libutti, James C. Yao, Roberto Buzzoni, Lorenzo Antonuzzo, Richard Hubner, Rocio García-Carbonero, Ana B. Custodio, Edward M. Wolin, Sabine Turri, Debarshi Dey, Paola Aimone, Joseph Sulovski, Nabanita Mukherjee, Fabian Herbst, Nicola Fazio
Journal: Journal of Clinical Oncology (2015)

4102 Background: The PI3K/AKT/mTOR signaling pathway is upregulated in pNET. Everolimus (EVE) is an mTOR inhibitor (mTORi) approved to treat advanced pNET, but resistance occurs. PI3K pathway activation is associated with mTORi resistance. The dual mTOR/PI3K inhibitor BEZ235 (BEZ) may provide enhanced antitumor effects. Methods: Ph II studies (Study [S]1 [NCT01628913]; S2 [NCT01658436]) investigated BEZ in patients (pts) with advanced pNET. S1 enrolled pts with disease progression within 12 months (mo) and no prior mTORi, who were randomized 1:1 to BEZ (400 mg BID) or EVE (10 mg QD). Stage 1 of S2 (single arm) enrolled pts with advanced pNET after mTORi failure, who received BEZ (400 or 300 mg BID [starting dose reduced]). Primary endpoint for S1 was progression-free survival (PFS) assessed only for descriptive purposes, and 16-week (wk) PFS rate for S2. Interim futility analysis was performed after stage 1 of S2 (31 pts observed ≥16 wk). Futility rejection criteria: ≥60% 16-wk PFS rate and ≥0.9 posterior probability of 16-wk PFS rate ≥40%. Results: At database lock, treatment discontinuation was 87% of pts in BEZ arm and 71% in EVE arm of S1, and 94% in S2, mainly due to progressive disease (S1: BEZ 36% vs EVE 45%; S2: 48%) and adverse events (AEs [S1: BEZ 39% vs EVE 16%; S2: 36%]). All-grade AEs regardless of study treatment relationship (≥35%) are listed. Median PFS in S1 was 8.2 mo (95% CI: 5.3–NE) and 10.8 mo (95% CI: 8.1–NE), for the BEZ and EVE arms, respectively; hazard ratio 1.53 (95% CI: 0.72–3.25). In S2, 16-wk PFS rate was 52% (90% CI: 35.7–64.3); posterior probability that 16-wk PFS rate is ≥40% was 0.9 (futility criteria met). Conclusions: BEZ as 1st- and 2nd-line (post-mTORi) therapy had limited clinical activity. S1 showed BEZ was not better tolerated than EVE; in S2, poor tolerability after EVE led to dose reduction. Clinical development of BEZ in pNET was terminated, but targeting the PI3K pathway warrants further exploration. Biochemical response data in S1 will be presented at the meeting. Clinical trial information: NCT01628913 and NCT01658436. AEs (%) S1 S2 BEZ 400 mg BID N=31 EVE 10 mg QD N=31 BEZ 300 or 400 mg BID N=31 Diarrhea 90 55 71 Stomatitis 74 65 36 Nausea 55 32 48 Vomiting 48 23 32 Asthenia 42 42 23 Abdominal pain 39 26 26 Rash 36 42 16 Hyperglycemia 32 36 36 Decreased appetite 29 42 26 Anemia 26 36 –
Self-assembled 20-nm 64Cu-micelles enhance accumulation in rat glioblastoma
Authors: Jai Woong Seo, JooChuan Ang, Lisa M. Mahakian, Sarah Tam, Brett Fite, Elizabeth S. Ingham, Janine Beyer, John Forsayeth, Krystof S. Bankiewicz, Ting Xu, Katherine W. Ferrara
Journal: Journal of Controlled Release (2015)
B7-h3-specific engager T cells for the immunotherapy of pediatric solid tumors
Authors: Christopher DeRenzo, David Torres, Victoria Tobin, Phuong Nguyen, Xiao-Tong Song, Stephen Gottschalk
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts B7-H3 positive tumors, including osteosarcoma, neuroblastoma, and high grade glioma, cause significant morbidity and mortality despite aggressive multimodality treatments. Current B7-H3-targeted immune-therapies take advantage of the monoclonal antibody 8H9, which is actively
Blood Pressure Response to Exercise in Hypertensive Subjects Exposed to High Altitude and Treatment Effects
Authors: Sergio Caravita, Andrea Faini, Grzegorz Bilo, Francisco C. Villafuerte, Josè Luis Macarlupu, Morin Lang, Elisabetta Salvioni, Miriam Revera, Andrea Giuliano, Francesca Gregorini, Giuseppe Mancia, Piergiuseppe Agostoni, Gianfranco Parati
Journal: Journal of the American College of Cardiology (2015)
Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients
Authors: Iman Doostan, Stacy L Moulder, Kelly K Hunt, Khandan Keyomarsi
Journal: Cancer Research (2015)

Abstract Almost seventy percent of all breast cancer patients have estrogen receptor (ER) positive tumors requiring hormonal therapy. Aromatase inhibitors (AIs) are considered as the first line hormonal therapy for ER+ post-menopausal patients. However, resistance to these drugs remains a major challenge in clinic and the biology of such resistance is not clear. Previous studies have shown that cyclin E pathway, a key regulator in the G1 to S transition of cell cycle, is deregulated in breast cancer. Full-length cyclin E is abnormally cleaved into low molecular weight isoforms (LMW-E) that renders patients to poor survival. Here we hypothesize that cyclin E deregulation can confer resistance to AIs. To address this, we engineered aromatase overexpressing MCF7 cells to overexpress LMW-E under doxycycline inducible promoter. Full-length cyclin E, GFP and empty vector transfected cells were also generated and used as controls. Our results indicated that AIs inhibited proliferation by arresting the cells at G1 phase of the cell cycle. However, LMW-E expression significantly enhanced proliferation of the cells when treated with AIs. In addition, LMW-E bypassed G1 arrest following AI treatment. At the molecular level, AIs decreased CDK2, pCDK2, and Rb levels and attenuated Rb phosphorylation. However, these effects were completely rescued only when LMW-E was expressed. Moreover, using an in vitro kinase assay we indicated that AIs decreased CDK2 kinase activity while LMW-E expression reversed this effect by increasing CDK2 enzymatic activity. Taken together, these results suggest that LMW-E inactivates Rb protein as a tumor suppressor and renders the cells to bypass G1 checkpoint following AI treatment. In addition, this study provides early evidence that CDK2 inhibitors could be beneficial in combination with AIs for LMW-E expressing tumors. Currently we are investigating whether LMW-E can bypass the activity of AIs using inducible breast cancer cell line xenograft. We are also examining the correlation between cyclin E status and response to treatment in a cohort of patients who received AIs in the neo-adjuvant setting. Citation Format: Iman Doostan, Stacy L Moulder, Kelly K Hunt, Khandan Keyomarsi. Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-05-05.
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects
Authors: Fang Tang, Rui Zhou, Zeneng Cheng, Guoping Yang, Aiqiao Chen, Zhi Liu, Hongyi Tan, Shuang Yang, Sanwang Li, Lingli Mu, Peng Yu
Journal: Acta Pharmaceutica Sinica B (2015)

The aim of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence of 2 formulations of agomelatine, and to investigate the pharmacokinetic properties of agomelatine in Chinese healthy male subjects. This was performed in a single-dose, randomized-sequence, open-label, four-way crossover study with a one-day washout period between doses. Healthy Chinese males were randomly assigned to receive 25 mg of either the test or reference formulation. The formulations were considered bioequivalent if 90% confidence intervals (CIs) for the log-transformed ratios and ratio of geometric means (GMR) of AUC and C max of agomelatine were within the predetermined bioequivalence range based on RSABE method. Results showed that both of the 90% CIs for the log-transformed ratios of AUC and C max of 7-desmethyl-agomelatine and 3-hydroxy-agomelatine were within the predetermined bioequivalence range. The 90% CIs for natural log-transformed ratios of C max, AUC0-t and AUC0-∞ of agomelatine (104.42-139.86, 101.33-123.83 and 97.90-117.94) were within the RSABE acceptance limits, and 3-hydroxy-agomelatine (105.55-123.03, 101.95-109.10 and 101.72-108.70) and 7-desmethyl-agomelatine (104.50-125.23, 102.36-111.50 and 101.62-110.64) were within the FDA bioequivalence definition intervals (0.80-1.25 for AUC and 0.75-1.33 for C max). The RSABE approach was successful in evaluating the bioequivalence of these two formulations.
A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors
Authors: M. Ranson, C. Dive, T. Ward, J. Cummings, K. Connolly, S. Evans, L. Robson, J. Durkin, J. Jolivet, D. Jodrell
Journal: Journal of Clinical Oncology (2006)

3059 Background: The X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein. AEG35156 is a synthetic 2nd generation antisense oligonucleotide to human XIAP that enhances cancer cell apoptosis preclinically as a single agent and in combination with chemotherapeutics. Methods: The primary objective was to establish the maximum tolerated dose (MTD) of AEG35156 given as a 7-day continuous infusion every 3 weeks. Other objectives were to determine AEG35156 pharmacokinetics, XIAP inhibition in peripheral blood mononuclear cells and in tumour cells where feasible and document anti-tumour activity. Results: Sixteen adult patients have completed at least one 7-day infusion. Two dose-limiting toxicities (DLT) were observed in five patients treated at 160 mg/m 2 /day: grade 3 thrombocytopenia for more than 7 days and grade 3 ALT and AST elevation. Seven patients have been treated at 125 mg/m 2 /day with one DLT of grade 3 transaminase elevation. An approximately 50% decrease in XIAP mRNA was seen in peripheral blood leucocytes three days after the start of infusions at 160mg/m 2 /day. One patient with small lymphocytic non-Hodgkin’s lymphoma had marked but short lived decreases in peripheral lymphoblasts during AEG35156 administration closely associated with XIAP mRNA knockdown. One patient with breast cancer had an unconfirmed partial response. The trial has now been amended to also determine the MTD of a 3-day continuous infusion every 3 weeks. Three patients have been treated with 3-day infusions at 160mg/m 2 /day every 3 weeks with no significant toxicities observed and patients are currently being accrued at 213mg/m 2 /day. Conclusions: AEG35156 can be safely delivered by continuous infusion and preliminary evidence of XIAP mRNA knockdown and antitumour activity has been observed. [Table: see text]